STOCKHOLM, den 23 augusti 2023 – I Lipidors delårsrapport för det andra kvartalet 2023, som publicerades idag 08:30, redovisades felaktiga siffror för jämförelseperioden jan-jun 2022. I stället återgavs jan-jun 2021. Korrigerad kvartalsrapport finns att hämta på bolagets hemsida lipidor.se samt i form av bifogad pdf. För att läsa kvartalsrapporten klicka här: https://lipidor.se/lipidor-ab-delarsrapport-q2-2023/ Offentliggörande Informationen lämnades för […]
STOCKHOLM, Sweden, 23 August 2023 – In Lipidor's interim report for the second quarter 2023, published today at 08:30, incorrect figures were reported for the comparison period Jan-Jun 2022. Instead, Jan-Jun 2021 figures were included. The corrected quarterly report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly […]
STOCKHOLM, Sweden, 23 August 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2023. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/lipidor-ab-delarsrapport-q2-2023/ Summary of interim report […]
STOCKHOLM, den 23 augusti 2023 – Idag publicerar Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) sin delårsrapport för perioden januari – juni 2023. Kvartalsrapporten finns att hämta på bolagets hemsida lipidor.se samt i form av bifogad pdf. För att läsa kvartalsrapporten klicka här: https://lipidor.se/lipidor-ab-delarsrapport-q2-2023/ Sammanfattning av delårsrapporten Det operativa arbetet har bestått av […]
STOCKHOLM, den 24 augusti 2022 – Idag publicerar Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) sin delårsrapport för perioden januari – juni 2022. Kvartalsrapporten finns att hämta på bolagets hemsida lipidor.se samt i form av bifogad pdf. Sammanfattning av delårsrapporten Under maj meddelades att hälften av patienterna i Lipidors Fas lll-studie med AKP02, […]
STOCKHOLM, Sweden, 24 August 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2022. The report is available on the company's website lipidor.se and in the attached pdf. Summary of interim report In May, it was announced that half of the patients […]
STOCKHOLM, Sweden, 24[th] August 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2021. The quarterly report is available on the company's website (click here (https://lipidor.se/lipidor-ab-delrsrapport-q2-2021/)) and in the attached pdf (in Swedish). Summary of the interim report – second quarter 2021 Lipidor has had […]
STOCKHOLM, den 24 augusti 2021: Idag publicerar Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) sin delårsrapport för perioden januari – juni 2021. Kvartalsrapporten finns att hämta på bolagets hemsida (klicka här (https://lipidor.se/lipidor-ab-delrsrapport-q2-2021/)) samt i form av bifogad pdf. Sammanfattning av delårsrapporten – andra kvartalet 2021 Lipidor har haft ett intensivt första halvår med framgångar inom många […]
In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under the EU Market Abuse Regulation. This was incorrect as the interim report for H1 2020 contains no insider information. This has been corrected in this press release. Today, Lipidor AB publishes its interim […]
Today, Lipidor AB publishes its interim report for the period January – June 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and in the attached pdf. Summary of the interim report – second quarter 2020 Lipidor has continuous positive ongoing out-licensing discussions with potential licensees. Preperations for initiation of the phase lll-study […]